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ABSTRACT 
Heart failure resulting from different forms of cardiomyopathy is defined as the inability 
of the heart to pump sufficient blood to meet the body’s metabolic demands. It is a major 
disease burden worldwide and the statistics show that 50% of the people who have the 
heart failure will eventually die from sudden cardiac death (SCD) associated with an 
arrhythmia. The central cause of disability and SCD is because of ventricular arrhythmias.  
Genetic mutations and acquired modifications to RyR2, the calcium release channel from 
sarcoplasmic reticulum, can increase the pathologic SR Ca
2+
 leak during diastole, which 
leads to defects in SR calcium handling and causes ventricular arrhythmias. The 
mechanism of RyR2 dysfunction includes abnormal phosphorylation, disrupted 
interaction with regulatory proteins and ions, or altered RyR2 domain interactions. Many 
pharmacological strategies have shown promising prospects to modulate the RyR2 as a 
therapy for treating cardiac arrhythmias. 
Here, we are trying to establish a novel approach to designing new drugs to treat heart 
failure and cardiac arrhythmias. Previously, we demonstrated that all pharmacological 
inhibitors of RyR channels are electron donors while all activators of RyR channels are 
electron acceptors. This was the first demonstration that an exchange of electrons was a 
common molecular mechanism involved in modifying the function of the RyR. Moreover, 
we found that there is a strong correlation between the strength of the electron 
donor/acceptor, and its potency as a channel inhibitor/activator, which could serve as a 
basis and direction for developing new drugs targeting the RyR.  
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In this study, two new potent RyR inhibitors, 4-methoxy-3-methyl phenol (4-MmC) and 
the 1,3 dioxole derivative of K201, were synthesized which are derivatives of the known 
RyR modulators, 4-chloro-3-methyl phenol (4-CmC) and K201. The ability of K201, 1,3 
dioxole derivative of K201 and 4-MmC to inhibit the cardiac calcium channel is 
examined and compared at the single channel level. All of these compounds inhibited the 
channel activity at low micromolar concentrations or sub-micromolar concentrations.  
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CHAPTER I 
INTRODUCTION 
1.1 INTRODUCTION 
Heart failure resulting from different forms of cardiomyopathies is characterized by the 
inability of the heart to pump sufficient blood to meet the body’s metabolic demands[1].  
Heart failure is a major disease burden worldwide and statistics show that 50% of the 
people who have heart failure will die from sudden cardiac death (SCD) associated with 
an arrhythmia.  
Genetic mutations and acquired modifications on cardiac ryanodine receptor (RyR2) can 
increase the pathologic sarcoplasmic reticulum (SR) Ca
2+
 leak during diastole, which 
leads to defects in SR calcium handling and causes ventricular arrhythmias [2, 3]. The 
mechanisms of RyR2 dysfunction include abnormal phosphorylation, disrupted 
interaction with regulatory proteins and ions, or altered RyR2 domain interaction[4]. One 
pharmacological strategy that has shown promise is to modulate the RyR2 as a therapy 
for treating cardiac arrhythmias.  
In this study, the molecular mechanism of how three drugs, K201, the dioxole derivative 
of K201 and 4-methoxy-3-methyl-phenol, modify the activity of sheep heart RyR2 will 
be investigated. 
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1.2 MUSCLE 
Muscle is a contractile tissue that is composed of bundles of fibers, which constitute from 
a third to a half of the bulk of vertebrates. It can produce motion for some useful 
functions, such as heat generation, circulation and digestion. The sizes and shapes of 
muscles vary, depending on the different types of tasks that muscles must perform. The 
longer a muscle, the more it can shorten and the higher its peak velocity of shortening; In 
contrast, the thicker a muscle, the more force it can develop. 
According to its morphology and different modes of contraction, muscle can be classified 
as skeletal, cardiac and smooth muscle. Skeletal and cardiac are together known as 
striated muscles because of the striped appearance of their fibers, in alternating bands of 
light and dark when observed under a microscope. Although skeletal and cardiac muscle 
have similar structure, they are controlled by different mechanisms. Skeletal muscle 
which is consciously controlled by the nervous system is known as voluntary muscle, 
whereas cardiac muscle is activated through involuntary pathways. Smooth muscles, 
consisting of enlongated fusiform cells, are also examples of involuntary muscle. They 
contract relatively slowly and have the ability to maintain contraction for a long period of 
time.  
1.2.1 CARDIAC MUSCLE ANATOMY 
Cardiac muscle is a type of involuntary striated muscle found in the walls of the heart. It 
resembles skeletal muscle in that both muscle types contain actin and myosin filaments, 
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and they contact through the sliding filament mechanism. Whereas skeletal muscle fibers 
are long, fibrous and are functionally separated from one another, cardiac muscle cells 
are short, branched and interconnected. Cardiac muscle also has a well developed T-
tubule system. T-tubules in cardiac muscle appear to be larger, broader and run along the 
Z Discs. Figure 1.1 shows a longitudinally arrayed, striped pattern of cardiac myofibrils, 
which comprise the I bands, A bands, and Z bands. Each longitudinal unit of myofibrils is 
called a sarcomere.  
Unlike the other muscle types, cardiac muscles have intercalated discs (IDs) that connect 
the individual myocytes together. The IDs are perpendicular to the direction of muscle 
fibres. They consist of three different types of cell-cell junctions, one of which is called a 
gap junction. Gap junctions are responsible for electrochemical and metabolic coupling, 
which allows an action potential to easily and quickly spread to all cells of the heart. 
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Figure 1.1 Transmission electron micrograph of ventricular walls [5]. 
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1.2.2 CARDIAC MUSCLE FUNCTION 
The cardiac myocyte has a negative membrane potential at rest and is responsible for 
contraction of the atria and ventricles of the heart. Unlike skeletal muscle, the cardiac 
muscle cells communicate with each other directly by passing the action potential (AP) to 
their neighbors through synaptic gap-junctions.  In addition, cardiac muscle is able to 
produce action potentials automatically through groups of specialized cells called 
pacemaker cells which are located on the atria.  
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1.3 FUNCTION AND REGULATION OF THE CARDIAC CALCIUM 
RELEASE CHANNEL 
1.3.1 SARCOPLASMIC RETICULUM 
The sarcoplasmic reticulum (SR) is a convoluted structure lying on the surface of the 
myofibrils and bounded by a membrane, which is specialized for the cyclical uptake, 
storage, and release of calcium ions. It plays an important role in muscular contraction 
and relaxation by regulating cytosolic Ca
2+
 concentration. As the calcium is taken up into 
the SR, the cytosolic Ca
2+
 concentration is lowered and muscle relaxes. Releasing the 
Ca
2+
 from the SR into the cytosol initiates muscle contraction. Two key proteins are of 
significant importance in regulating the cytosolic Ca
2+
 concentration — the ryanodine 
receptor (RyR) and the calcium pump.  
Structurally, the SR can be divided into two portions, the terminal cisternae and the 
longitudinal cisternae (Fig 1.2). The terminal cisternae are closely apposed to the T-
tubule and contain a large amount of calcium binding proteins. Vesicles derived from 
terminal cisternae also known as heavy SR, contain a large density of calcium release 
channels. The longitudinal cisternae are mainly composed of calcium pumps and rarely 
contain calcium binding proteins. SR vesicles derived from the longitudinal SR are 
referred to as light SR (LSR). The SR is connected to T-tubule by feet-like projections in 
the region of the terminal cisternae. This region, known as junctional SR, is concerned 
with transmission of the impulse from the T-tubule to the SR causing calcium release. 
The transverse tubule system and terminal cisternae together is called the triad. 
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Figure 1.2. Diagrammatic representation of the sacoplasmic reticulum(SR) showing its 
regular arrangement with respect to the myofibrils [6].  
 
8 
 
1.3.2 SRUCTURE AND FUNCTION OF THE RYANODINE RECEPTOR 
The calcium release channel is a ligand-gated channel also known as the ryanodine 
receptor (RyR), the function of which is to release Ca
2+
 ions rapidly from its lumen into 
the cytosol and trigger the contractile mechanism of the muscle fiber. There are three 
subtypes of RyR isoforms, the labeling of which is based on the chronological order of 
their initial purification. Those isoforms are isolated from a variety of tissues and exhibit 
different pharmacological properties. Subtypes of 1 and 3 of RyR isoforms have been 
shown to appear in early stages of skeletal muscle development. However, in adult 
animals, RyR1 is predominantly found only in all skeletal muscles while RyR3 display a 
differential distribution, having been observed in smooth muscle and brain. In cardiac 
myocytes, RyR2 has been shown to be expressed.  
Fig 1.3 shows a 3D structure of the RyR. The size is determined to be 28*28*12nm. It is 
a homotetramer, consisting of four individual subunits and each individual protein has an 
approximately molecular weight of 564 kDa [7]. The microscopic image reveals RyR1 
has four- fold symmetry with a large cytoplasmic domain and a relatively small 
transmembrane region. The central cavity has a diameter of approximately 2nm and is 
connected to four peripheral channels that extend from partway across the membrane to 
the cytoplasmic end. The rest of the protein lying between the T-tubule and SR 
membrane is known as the foot region, which links the Ryanodine receptor to the DHPR 
in the T-tubule membrane. It provides a direct physical interaction between the voltage 
sensing protein in the T-tubule membrane and the SR calcium release channel. 
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Figure 1.3 3D reconstruction of the ryanodine receptor [8] 
It is shown in three different views. View from cytoplasm, view from SR lumen and side 
view. The transmembrane region of RyR is shown in a side view with the SR luminal 
face down. 
 
Three major proteins with high affinity for calcium are involved in regulation of muscle 
contraction. 
Calmodulin 
Calmodulin (CaM) is a binding protein with a molecular weight of 16.8 KD and contains 
four calcium binding domains [9]. Each domain contains 12 amino acid residues forming 
a “pocket” for a Ca2+ ion. CaM binds directly to the RyR and decreases channel opening 
at concentrations at around 2 µM. As a calcium sensor and signal transducer, CaM binds 
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to and activates many proteins that are unable to bind calcium themselves. It can bind up 
to four calcium ions, and can undergo post-translational modifications, such as 
phosphorylation, acetylation, and methylation. 
Triadin 
Triadin is a transmembrane protein with molecular weight of 95 KD. It was discovered in 
1990 [10] and was originally proposed to play a critical role in E-C coupling. However, 
many researchers later showed that triadin only indirectly influences E-C coupling. 
Triadin is associated with the RyR, calsequestrin and junctin to form a macromolecular 
calcium signaling complex in the junctional SR [9]. This association facilitates cross-talk 
between calsequestrin and the RyR. Junctin was later discovered [11] and it is believed to 
have a comparable function to triadin, due to its similar structure and ability to bind both 
calsequestrin and the RyR. 
Calsequestrin 
Calsequestrin, the second most abundant protein constituent of the SR, is a low affinity 
high capacity calcium-binding protein. It functions as a calcium buffer in the SR lumen. 
It readily releases Ca
2+
 when the calcium release channel in the SR opens. 
FKBP12 / FKBP12.6 
FKBP, also known as FK506 binding protein, is considered an integral part of the 
functional Ca
2+
 release channel. It belongs to the family of immunophilins and is a 
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receptor for the immunosuppressive drugs FK-506 and rapamycin. It is believed that 
dissociation of FKBP12 / FKBP12.6 from the RyR1/RyR2 of SR increases the channel 
activity and the sensitivity of the channel to agonists such as Ca
2+
 and caffeine, and 
decreases the sensitivity to blockage by Mg
2+
. Rebinding of FKBP 12 restores these 
channel characteristics. A related protein, FKBP 12.6, is found in cardiac muscle, which 
modified the channel activity in a similar way. 
1.3.3 REGULATION OF CALCIUM RELEASE CHANNEL 
Calcium release channel (CRC) channel activity is regulated by a wide variety of 
endogenous molecules. Physiological ligand activators of the RyR include the 
dihydropyridine receptor (the voltage-sensor), Ca
2+
 at micromolar levels, and millimolar 
concentrations of ATP. Inhibitors include Ca
2+
 and Mg
2+
 at millimolar concentrations. 
Table 1.1 lists some of the modulators of the CRC. 
Ca
2+
, Mg
2+
 and ATP are three key regulators of the channel. Ca
2+
 is thought to be the 
physiological channel activator because other ligands either cannot activate the channel 
in its absence or they require Ca
2+
 for maximum effect. Ryanodine binding assays, SR 
Ca
2+
 flux measurements and single channel recordings have shown that cytosolic Ca
2+
 
has a biphasic effect on skeletal muscle RyR channel activity. The threshold 
concentration for channel activity is around 100 nM, while maximum activity is observed 
in the range of 10-100 µM. Millimolar concentrations of Ca
2+
 inhibit the channel. The 
biphasic effect of Ca
2+
 on channel activity suggests that RyR1 contains high-affinity 
Ca
2+
-binding sites that stimulate the channel and inhibitory low-affinity binding sites. 
12 
 
 
Table 1.1 Modulators of the SR RyR Channel 
ACTIVATORS INHIBITORS 
Ca
2+
 (µM) Ca
2+
 (>1 mM), Mg
2+
 (mM) 
Ryanodine (100 nM-10 µM) Ryanodine (100-300 µM) 
Quinones, Porphyrins Ruthenium red (0.1-5 µM) 
Doxorubicin(a quinone) Tetracaine, Procaine 
Caffeine Verapamil 
Pelargonidine Polyunsaturated fatty acids 
Cu
2+
 / cysteine 7-diethylamino-3-(4-
maleimidolphenyl)-4-methylcoumarin 
(CPM) 
Rose Bengal Calmodulin 
GSSG Lactate 
4-CmC K201 and its dioxole derivative 
Sulfhydryl oxidizing agents Thiol reducing agents 
 
Mg
2+
 is a potent CRC inhibitor and inhibits RyR in a dose dependent manner, with 
millimolar concentrations resulting in complete inactivation. It has been suggested that 
Mg
2+
 exerts its inhibitory effects by competing with Ca
2+
 for the high-affinity Ca
2+
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stimulatory sites and by binding to the low-affinity inactivation sites with an affinity 
comparable to Ca
2+
. 
The adenine nucleotides ATP, ADP, AMP and cyclic-AMP, as well as adenine, are 
activators of RyR channel. It has been suggested that ATP increases the sensitivity of the 
channel to Ca
2+
 and decrease its sensitivity to Ca
2+
 inactivation. 
The CRC from SR also can be regulated by altering its redox status. RyR is rich in thiol 
groups. The oxidation / reduction of those thiol groups by thiol reagents can activate / 
inhibit the CRC. Conditions that favor channel opening, such as making the redox 
potential of the RyR more negative. The RyR favors the oxidation of thiols, whereas 
conditions that close down the channel have the opposite effect. However, most channel 
modulators are non thiol reagents. Previous research in our lab showed that most of the 
non-thiol channel activators acts as electron acceptors, and channel inhibitors act as 
electron donors in free radical reactions [12]. Non-thiol channel regulators can shift the 
thiol-disulfide balance within CRC by transiently exchanging electrons with the Ca
2+
 
release protein. 
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1.4 EXCITATION-CONTRACTION COUPLING IN HEART 
1.4.1 E-C COUPLING IN HEART 
Fig 1.4 shows the key cellular components involved in EC coupling and calcium 
movement. Unlike skeletal muscle cell, there is no directly physical interaction between 
the dihydropyridine receptor (DHPR) (also known as the L-type Ca
2+
 channel) and RyR2 
during EC coupling. When an action potential is initiated, the myocyte depolarizes and 
extracellular Ca
2+
 enters the cell through the DHPR. This inward Ca
2+
 current acts as an 
amplifier and in turn activates the RyR2 channels to release Ca
2+
 from the SR, which 
triggers contraction. This process is called “calcium induced calcium release” (CICR). It 
has been reported that the opening of a single DHPR channel triggers calcium release 
from 4-6 RyR2 channels [13]. Muscle relaxation is followed by the closure of RyR2 and 
rapid removal of cytosolic calcium, by reuptake of Ca
2+
 into the SR through the SERCA2 
protein, and by efflux of Ca
2+
 out of cell by the Na
+
/Ca
2+
 exchange protein (NCX). 
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Fig 1.4 Schemetic of cardiomyocyte excitation- contraction coupling. Major components 
of EC coupling within a myocyte are shown [14]. 
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1.4.2 ACTION POTENTIAL 
The excitation and contraction coupling process in cardiac myocytes starts with the action 
potential. There are two types of cardiac action potentials in heart, fast response action 
potentials and slow response action potentials. The fast response action potentials, also 
called non-pacemaker action potentials, can be found throughout the heart except for the 
pacemaker cells. The duration of this action potential is around 200 ms to 400 ms 
depending on different animal species. 
Fig 1.5 shows the time course of a normal action potential. Before the cell is stimulated 
by the electrical signal, the cardiac myocytes are at a resting membrane potential, which 
is -80 mV. As cells are stimulated, an inward small flux of Ca
2+
 and Na
+ 
through gap 
junction occurs and the membrane potential is increased slightly to reach a threshold. 
This increase in the membrane potential opens the fast Na
+
 channels and causes a large 
influx of Na
+ 
into the cell, which results in a rapidly depolarization of the cell membrane. 
After the rapid depolarization, there is a long lasting phase to the action potential, during 
which the potassium leaves the cell through the slow delayed rectifier potassium channels 
and the calcium enters the cell through L-type calcium channels. The deflection at the 
beginning of this stage was caused by the outward K
+ 
current. As the potential slowly 
comes down, the L- type Ca
2+
 channels close while the slow delayed rectifier K
+
 channels 
are still open. This leads to a negative change in membrane potential and tends to open 
the outward rapid delayed rectifier K
+
 channel. This net outward current causes the cell to 
repolarize to its resting potential.  
17 
 
 
 
Fig 1.5. Cardiac Action Potential [15] 
 
 
 
  
18 
 
1.5 RYANODINE RECEPTOR-MEDIATED ARRHYTHMIAS AND HEART 
FAILURE 
Heart failure is a major disease which is responsible for >300,000 deaths per year in the 
US alone. 50% of the people who have the heart disease will eventually die from sudden 
cardiac death (SCD) associated with an arrhythmia. The cardiac disturbance is usually 
caused by alterations in the expression or function of several key proteins involved in 
regulating and maintaining ionic homeostasis [16]. Ryanodine receptors are one of the 
most important groups of such proteins. Rapid release of Ca
2+
 by the sarcoplasmic 
reticulum membrane in the heart induced by Ca
2+
 via the RyR2 receptor is a critical step 
in cardiac contractility. The malfunction of RyR2 can result in diastolic Ca
2+
 leak and 
cause a delayed after depolarization (DAD), which is a major feather of arrhythmias in 
HF [17]. 
1.5.1 MOLECULAR MECHANISMS OF RYANODINE RECEPTOR TYPE-2 
DYSFUNCTION 
The molecular mechanism of ryanodine receptor dysfunction is highly controversial. 
There are two main hypothesizes. The hyperphosphorylation hypothesis suggests that the 
hyperphosphorylation of RyR2 is caused by the loss of two phosphatases (PP1 and PP2A) 
and results in the debinding of the modulator protein FKBP12.6 from the RyR2 complex, 
which destabilizes the channel [18]. Several research groups have shown that the 
treatment with β blocker reversed PKA-mediated hyperphosphorylation of RyR2 [19, 20]. 
restored cardiac function and reduced the rate of mortality in patients with HF [21, 22]. 
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Several RyR2 phosphorylation sites have been found that are related to HF. The S2809 
residue has been shown to be hyperphosphorylated during HF in myocardium from in a 
removed human heart [18]. An alternative hypothesis suggests that the gating of channel 
is regulated by ‘unzipping’ of interacting domains within the RyR2 molecule [23]. 
1.5.2 CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR 
TACHYCARDIA (CPVT) 
CPVT is an inherited disorder associated with mutations in either the RyR2 (CPVT1) or a 
SR luminal protein, calsequestrin (CVPT2). Patients with CPVT have structurally normal 
hearts and present with ventricular arrhythmias at physical or emotional stress. 69 point 
mutations were found in the RyR2 gene in 253 (out of 915) patients screened for 
CPVT1and this number is growing [4]. On the other hand, only a few patients have been 
identified with CPVT2 symptoms which have mutations in the calsequestrin.  
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1.6  THE HYPOTHESIS UNDERLYING THE DESIGN OF NEW DRUGS TO 
MODIFY RYANODINE RECEPTOR FUNCTION 
In this study, we are trying to establish a novel approach to design new drugs to treat 
dysfunctions associate with RyR. It has been shown that there are a large number of 
chemically diverse compounds which can either activate or inhibit the SR Ca
2+
 release 
channel. The common characteristic of most channel activators is their ability to act as 
electron acceptors, and common to the channel inhibitors is their electron donor 
characteristics. Moreover, we find that there is a strong correlation between the strength 
of the electron donor/acceptor, and its potency as a channel inhibitor/activator [12]. It 
occurred to us that this could serve as a basis and direction for developing new drugs 
targeting the RyR. 
The redox activity of drugs and proteins that interact with the Ca
2+
 release channel is a 
key factor in modifying function of the SR.  It is well established that thiol reducing 
agents inhibit RyR, while thiol oxidizing agents activate the release channel. Reduction 
of endogenous disulfides on the RyR1 inhibits the flux of Ca
2+
 across the SR [24] , 
channel activity, and high affinity ryanodine binding [25]. The hypothesis that novel 
drugs with enhanced electron donor properties act as more potent inhibitors of RyR is 
consistent with the role of redox reactions in channel gating.  
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CHAPTER Ⅱ 
GENERAL METHODS AND MATERIALS 
2.1 MATERIALS 
2.1.1 PREPARATION OF CARDIAC SARCOPLASMIC RETICULUM 
Cardiac sarcoplasmic reticulum vesicles were isolated from sheep ventricles. The sheep 
heart was removed from host animal upon anesthetization and kept in the homogenization 
buffer containing 10 mM imidazole, 3 mM NaN3, 0.29 M sucrose, 1µg/ml leupeptin and 
a protease inhibitor tablet (sigma # S8830) at pH6.9. The heart was bled and both the left 
and right atria were discarded. The remaining ventricles were cleaned by removing all the 
exterior and interior fat and connective tissue.  
Upon preparation, 80 g of cardiac ventricles from a single sheep heart were minced and 
placed in 1 L homogenization buffer. The mixture was blended for 15 seconds at low 
speed and three times 15seconds at high speed. The homogenate was poured into 6 Type-
19 tubes and then centrifuged at 9000 rpm for 19 mins in a Beckman type-19 rotor. The 
supernatant was filtered through 4 layers of cheesecloth and centrifuged for 75 mins at 
19000 rpm in the Beckman type-19 rotor. The supernatant from this spin was carefully 
poured into a beaker and the brown pellet was resuspended in KCl buffer which contains 
0.65 M KCl in homogenization buffer at pH 6.7. The mixture was distributed into two Ti-
60 tubes and incubated on ice for 30 mins. The incubated sample was centrifuged at 5000 
rpm for 11 mins in Ti-60 rotor. The supernatant from this step was transferred to two 
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other clean Ti-60 tubes and the pellet was discarded. The supernatant was spun at 50,000 
rpm for 30 mins in Ti-60 rotor. The resulting supernatant was discarded and the pellets 
were carefully removed and placed in a glass homogenizer. The combined pellets were 
then homogenized in 5 ml KCl buffer using a 7 ml manual glass homogenizer. The final 
sample was stored in liquid nitrogen in aliquots. This process yielded around 30 mgs of 
SR from the original 80 g of ventricles. 
2.1.2 DETERMINATION OF PROTEIN CONCENTRATION 
The protein concentration of the SR prep was determined from ultraviolet absorbance at 
230 nm, 260 nm, 280 nm wavelength according to the method of Kalckar (1947) [26].   
Aromatic amino acids, particularly tyrosine and tryptophan absorb in the ultraviolet at 
280 nm. Since most proteins contain these two residues, their concentration can be 
successfully estimated by measuring the absorbance at 280 nm wavelength. The 
absorbance peak at 230 nm is produced by the backbone peptide bonds. This method uses 
absorption characteristics at 280 nm and 230 nm wavelength to calculate the protein 
concentration, while the peak at 260 nm wavelength is used as a correction factor to 
cancel the possibility of contamination by nucleic acid. 
With absorbance measurements at these three wavelengths, the protein concentration can 
be calculated from follow simplified equations: 
(SR)mg/ml = 1.45 (Abs280) -0.74 (Abs260) 
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(SR)mg/ml = 185 (Abs230 )- 74.8 (Abs260) 
Three measurements are taken at each wavelength with increasing volumes of SR being 
added and the final protein concentration is calculated as a mean ± standard deviation.  
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2.2 PLANAR LIPID BILAYER 
2.2.1 METHOD 
Single-channel recording techniques with artificial bilayer membranes have been applied 
to various types of channel proteins in order to observe their physiological and 
pharmacological properties. It provides a method for observing the kinetic properties of 
individual ion channels.  
The bilayers were usually formed using a modification of the film drainage method 
developed by Mueller [27]. Lipid in a hydrophobic solvent was smeared across a hole in 
a plastic septum to produce a thick lipid film separating two baths. The bilayer forms 
spontaneously from this thick film. After the formation of bilayer, ion channel proteins 
are added. The incorporation of ion channels into membranes occur spontaneously and 
this can be detected by conductance changes in the bilayer. For studying SR ion channels, 
the bilayers are produced across an aperture with a diameter of approximately 100 µm. 
The final concentration of SR vesicles is usually around 1-10 µg/ml. The side of the bath 
to which vesicles are added is referred to as the cis side. Following fusion, this 
corresponds to the outside of the SR. The other side, trans, corresponds to the luminal 
side. There are several conditions that promote vesicle fusion: a gradient in osmotic 
strength across the membrane (cis high); cis [Ca
2+
] at µM concentration; and vigorous 
stirring of the cis bath. 
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This artificial membrane system, before incorporation of the Ca
2+
 release channel (CRC) 
is impermeable to both anions and cations. Cis and trans side are loaded with a buffer 
appropriate to the experiment and the bilayer is formed. Cesium methane sulfonate 
(Cs
+
CH3O3S
-
) is commonly used as the principal salt in the bath solution, since CH3O3S
-
 
is unable to cross the membrane through any SR pore and Cs
+ 
is the only ion channel 
permeable charge carrier. This prevents current signals from other ion channels from 
interfering with CRC recordings.  
When the SR fuses with a bilayer, ionic conductance, as well as open and close state, can 
be monitored by measuring the current through the membrane in response to an applied 
electrochemical gradient. This allows us to examine the response of channel to a variety 
of substances in the cytosolic and luminal baths and also changes in the composition of 
the bilayer itself. 
2.2.2 PROCEDURE 
Figure 2.1 A shows a overview of the bilayer lipid membrane (BLM) setup in Dr 
Abramson’s lab. The amplifier and the signal generator (Warner BC-525A) is the center 
of the apparatus. Ag/AgCl electrodes were inserted into a preamplifier to detect current. 
Salt bridge (4 M CsCl, agarose) provides an interface for the exchange of ions while 
preventing the introduction of silver into the bilayer solution. The amplified signal 
interfaced into an Axon Instruments Digidata 1322A digitizer was recorded by the 
ClampEx patch clamp chart recorder from the Axon Instruments pClamp 9.0 software 
package. The bilayer chamber consists of a cup with a 150 to 200 µm hole of a thin 
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walled region midheight and a base holder. The holder contains a subtracted column 
sufficient to snuggly hold the cup and to provide room for the outer solution. The 
chamber is placed in a Faraday cage to electrically isolate it from the outside.  
The SR that was used for bilayer experiments was prepared from a crude SR prep which 
was diluted to 1 mg/mL in a sucrose/ CsMeSO3 buffer. Planar lipid bilayers were formed 
with 5 mg/mL of a 5:3:2 ratio of PE: PS: PC (PE: 1,2-Dioleoyl-sn-Glycero-3-
Phosphoethanolamine; PS: 1,2-Dioleoyl-sn-Glycero-3-[phosphor-L-Serine]; PC: 1,2-
Dioleoyl-sn-Glycero-3-phosphocholine) suspended in chloroform. The solvent was 
evaporated with a stream of N2 gas and resuspended in decane at a final concentration of 
70 µg/µL. 
Cesium methane sulfonate (Cs
+
CH3O3S
-
) buffer was used in all experiments and Cs
+
 is 
the only membrane permeable charge carrier.  
The experiment was started in the presence of 400: 40 mM cis: trans Cs
+
CH3O3S
-
 
gradient at a holding potential of +36 mV to promote the fusion of SR vesicles. 
Following the fusion, the trans Cs
+
 concentration was brought up to 400 mM to prevent 
subsequent fusion events. 
Traces of not less than 1min were recorded and channel output was filtered at 800-1000 
Hz. Single channel activity was tested with addition of different modulators to the cis 
side of the bilayer. All the recorded traces were analyzed using the ClampFit 9.0. 
2.2.3 ANALYSIS 
27 
 
Analysis of single channels is largely automated in Clampfit 9.0. The calculation of open 
probability and open and close times will be discussed in this section. These are the two 
most commonly used methods for analyzing and understanding single channel data. 
Event detection 
The major task of the single channel analysis program is to compile event lists. For a 
single channel analysis, an event is defined as a sudden change in current as the result of 
the opening or closing of an ion channel. These detected events are characterized and 
stored in an event table in the result window, which is then used for statistical analysis of 
channel current amplitudes and channel kinetics. The method adopted by this thesis for 
event detection uses a half amplitude threshold technique. Every crossing of the threshold 
is interpreted as an opening or closing of the channel. Moreover, the time spent above the 
threshold is taken as an estimate of the channel opening time.  
Open probability 
Po is the fraction of time the channel is in a conducting state. It is calculated from the 
ratio of the number of data points in a conducting level to the total number of points in 
the record. A value of 1 means that the channel is always open, while a value of 0 means 
that the channel is never open. 
As all of the open and close times have been measured from event detection analysis, Po 
can be calculated as total open time divided by total length of the record. If there is only 
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one open level, this is the same thing as the average current level throughout the record, 
divided by the open-channel current level.  
Clampfit also produces a time dependent graph of open probability. Open probability is 
almost never stable with time, so it is useful to seeing how long it took for chances to 
occur and for choosing a representative time period to make figures. 
Open and closed time 
The dwell-time distribution provides a more detailed and useful analysis of channel 
activity. Dwell time means the times spent at each current level before it jumps to a new 
value. An overall picture of channel gating rates is encapsulated in the mean open and 
closed dwell-times, referred to as τo and τc. Frequency histograms of open and closed 
dwell-times show the kinetic signature of the gating mechanism, and this distribution can 
be well described by the sum of decaying exponential functions. There are many ways to 
display these histograms, among which linear histogram and logarithmic histogram are 
two common types of plots to use. Logarithmic histograms developed by Sigworth and 
Sine [28] have been demonstrated a more useful plot [29]. In this method, the probability 
density, estimated by dividing the number of events in each bin by the bin width, is 
plotted on a log-log scale along with a log-log plot of the theoretical probability density 
function. All the single channel data in this thesis were analyzed by using this method. 
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A 
 
B 
 
Fig 2.1. A is a schematic representation of the BLM setup in the Abramson lab. B is a 
schematic showing SR vesicle fusion to the artificial membrane [30].  
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2.3 STUDENT T TEST 
The student T test uses the t-distribution that was developed by William Sealy Gosset in 
1908. It is often used to compare two small sets of quantitative data when samples are 
collected independently of one another. The t-test assumes that the observations within 
each group are normally distributed and the variances are equal in the two groups [31]. 
In order to perform a t-test on two independent samples which have unequal sample sizes 
and equal variance, the following equation were used.  
 
Where n1, n2,   ,   , and SX1, SX2 are sample size, mean value, and standard deviation 
for group one and two. 
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2.4 DYE PHOTOSENSITIZED ELECTRON DONOR/ ACCEPTOR TEST 
2.4.1 INTRODUCTION 
The dye photo bleaching experiment relies on the excitation of single electrons in dye 
molecules to a more reactive state, and on existence of a stable, non-reactive reduced 
state for quantifying the extent of the reactions. Fig 2.3 shows the basic mechanism 
involved in this assay. The first step in the reaction pathway is the formation of the high 
energy singlet state of the dye (
1
Dye
*
) by photo excitation with visible light. 
1
Dye
*
 then 
decays to a triplet state (
3
Dye
*
) spontaneously. Interaction between the triplet states by 
collision results in the production of short lived cation and anion radicals. In the aqueous 
solution, two dye anion radicals can interact with each other and form a stable reduced 
bleached state (Dye-H2). However, when there is no electron donor component present, 
the population of Dye
●−
 and Dye
●+
 is small and they recombine rapidly. Photo bleaching 
proceeds slowly.  
The electron acceptor property of a drug was examined in the presence of a sacrificial 
electron donor such as NADH or EGTA to increase the initial concentration of dye anion 
radicals. When there is no acceptor presented, the dye photo bleaching signal and in the 
presence of O2, the production of superoxide is maximized. Both the bleaching signal and 
superoxide production decreases after the addition of an electron acceptor. The difference 
between the rate of superoxide production and the dye bleaching in the presence and 
absence of the compound of interest is a measure of electron-acceptor activity of the 
compound. 
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In order to see whether a compound is an electron donor, the auxiliary donor was 
replaced with the reagent to be tested. If the compound tested is an electron donor, dye 
photo bleaching increases as does the production of superoxide, which is detected with 
XTT. 
Two similar dyes, the thiazine dye methylene blue (MB) and the xanthene dye eosin, 
were used in the electron donor/acceptor experiments. Both of dyes promote electron 
transfer and exhibit an excited triplet state when excited by visible light. The selection of 
which dye should be used in each experiment depends on the relation of dye absorbance 
spectra to wavelength of interest. 
The electron donor properties of FKBP12, K201 and its dioxole derivative, discussed in 
this paper, were tested using Methylene Blue (MB). Fig2.2 shows the structure of MB 
and its stable bleached form. MB has a sharp absorbance peak at 663 nm due to its 
conjugated ring structure. 
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Fig2.2 Initial and reduced structure of Methylene Blue. The conjugation of the rings is 
disrupted by the reduction resulting in the loss of the visible absorbance peaks [32]. 
 
 
 
 
 
 
34 
 
 
 
 
Fig 2.3 Scheme showing the protocol for measuring the electron acceptor/donor 
properties of reagents [12]. 
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2.4.2 PROTOCOL 
Experiments were carried out in the presence of O2. All electron donor experiments were 
conducted in 1 mM tris buffer (pH7.4). 20% DMSO may be required in some donor 
experiments to avoid dye aggregation effects. MB at concentration of 10 µM was used as 
the excited dye and superoxide production was detected with an optical probe XTT (2, 3-
Bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide) at 100 µM. The 
spectra changes were quantified by measuring the decreased bleaching signal at 663 nm 
and the increased absorbance at 470 nm as a function of time. All measurements are 
made with respect to a blank cuvette containing only Tris buffer. 
HP8452 diode array spectrophotometer was used in all experiments. Illumination was 
provided by a 50 W lamp positioned 2-3 cm above the sample. Measurements could be 
taken using a standard mode or kinetic mode. Similar result should be obtained with both 
types of modes. The only difference between these two modes is that in the standard 
mode, data was manually collected over a time interval fixed by the operator while in the 
kinetic mode, data was automatically collected by computer at a fixed time intervals. 
Initial rates were calculated using Sigmaplot 10.0 by fitting the data to a function called a 
two parameter exponential rise to maximum. The rate could be automatically calculated 
by the computer in the kinetic mode. 
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2.5 INTRODUCTION TO ANTIARRYTHMIC DRUGS 
2.5.1 K201 AND THE DIOXOLE DERIVATIVE OF K201 
K201, also known as JTV519, is a 1, 4-benzothiazepine derivative, which was developed 
by Kaneko [33] in the mid 1990s. Fig 2.4 shows the chemical structure of K201. It has 
been proposed that the drug can suppress the development of heart failure by inhibiting 
spontaneous calcium leakage from SR during the early stages of heart failure [34]. 
However, it also acts as a multi-channel blocker including K
+
 channels. The block of the 
inward rectifying K
+
 channel can result in prolongation of the cardiac action potential 
which is known as a proarrhythmic signal [35, 36]. 
Many efforts have been made to understand the basic mechanism of the action of K201. 
Some research groups show that the cardio-protective effectiveness is due to its ability to 
correct the defective FKBP12.6 control of RyR2 [34], while other labs argue for the 
inhibition effect of K201 on SR CRC being independent of the presence of the FKBP12.6 
protein [37]. Data presented in this thesis show that K201 is a strong electron donor and 
also a potent Ca
2+
 channel inhibitor independent of the presence or absence of FKBP12. 
According to our hypothesis, most channel inhibitors act as electron donors. Selective 
modification of the electron donor properties of a drug modifies its potency and 
effectiveness as a CRC inhibitor in a predictable manner. The 1,3dioxole derivative of 
K201, shown in Fig 2.5, was obtained by selective modification of the chemical structure 
of K201, resulted in a compound with enhanced electron donor properties. The syntheses 
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of the analog are based on published work which involves well-known and efficient 
chemistry [38] [33].  The data from bilayer experiments show that this derivative of K201 
is ten times more effect an inhibitor of RyR1 activity than its parent molecule [39]. 
Both K201 and its analogs used in this thesis were synthesized by Jorge Escobedo and 
Jialu Wang from Dr Strongin’s Lab at Portland State Unversity.  
 
Fig 2.4 Chemical structure of K201, a 4-[3-(4-benzylpiperidin-1-yl)propionyl]-7-
methoxy-2,3,4,5-tetrahydro-1,4-benzothiazepine monohydeochloride. 
 
 
Fig 2.5 Chemical structure of the dioxole derivative of K201 
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2.5.2 4-METHOXY-3-METHYL PHENOL (4-MmC) 
4-MmC is a derivative of 4-chloro-3-methyphenol (4-CmC). It was synthesized using the 
method reported by Higgins et al [40]. 4-CmC is a clinically proved activator of the 
intracellular Ca
2+
 release channel and also inhibits the calcium pump protein from SR at 
low millimolar concentration [41]. Chemical structures of both compounds are shown in 
fig 11. By substituting the chloro group with the methoxy group, we turned the electron 
acceptor 4-CmC into an electron donor, 4-MmC. Our previous study showed that 4-MmC 
is potent inhibitor of RyR1, with an the IC50 below 1µM [39]. 
4-MmC used in this study was synthesized by Dr. Strongin’s lab at Portland State 
University. 
 
Fig 2.6. Chemical structure of 4-Chloro-m-Cresol and 4-Methoxy-3-methylphenol 
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CHAPTER III  
RESULTS 
The single channel recording technique is a very powerful and versatile method for 
studying electrophysiological properties of biological membranes. It differs from other 
experiments, such as calcium efflux assays and ryanodine binding assays in that a single 
molecule is being probed, providing us the opportunity to observe the interaction with a 
single protein. All of the bilayer reconstitution works described in this study were done 
with sheep cardiac ventricular muscle SR vesicles which were fused with an artificial 
membrane as described in section 2.2. The SR vesicles were not exposed to detergent.  
In this chapter, the ability of K201, 1, 3 dioxole derivative of K201 and 4-Methoxy-3-
Methyl phenol in inhibiting the cardiac calcium release channel is examined and 
compared. Three drugs showed stronger potency in inhibiting the cardiac calcium release 
channel than the skeletal calcium release channel, and all of them inhibit the calcium 
release at low micromole concentrations or sub-micromolar concentrations. 
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3.1 K201 INHIBITS CARDIAC CALCIUM RELEASE CHANNEL (RyR2) 
The effect of K201 on single channel activity was tested in the presence of 0.1 µM Ca
2+
 
and 1 mM ATP added to the cis chamber of the bilayer setup, a condition that mimics the 
physiological environment in the cell. Different doses of K201 ranging from 50 nM~10 
µM, were added to the cis chamber, which corresponds to the outside face of SR (the 
cytoplasmic face). Six independent experiments were carried out under identical 
conditions. Fig 3.1 shows representative traces with addition of 0, 0.5, 1, 10 µM K201. 
There are two channels fused into the artificial membrane. The open probability (Po) was 
calculated from Clampfit as described in Chapter 2. As more than one channel present at 
the same time, the NPo for the trace is simply the sum of Pos for each channel. The open 
probability for control (Fig3.1 A) is 36.6%. K201 (0.5 µM) decreases the channel open 
probability to less than 15%. As shown, the open probability decreases as the K201 
concentration increases. The channel activity decreases dramatically at low drug 
concentrations ranging from 50 nM to 1 µM. Addition of K201 at concentrations >5 µM 
maximally inhibited the channel to less than 20% of control activity (Fig 3.2).  
In fig 3.2, normalized average open probabilities were plotted versus drug concentration 
and fit to a four parameter logistic curve in Sigma Plot 10. The IC50, the drug 
concentration that half inhibits release channel activity, is 1.13±0.68 µM, which is 1/3 of 
the IC50 observed to inhibit RyR1.  
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Fig 3.1 RyR2 is inhibited by K201 
Representative traces of RyR2 channel activity at 0.1 µM free [Ca
2+
], 1mM ATP on cis 
side: 400 mM CsMeSO4 on both side of the bilayer and -36 mV holding potential. 2s 
representative trace excerpts are shown. Open probabilities were obtained from traces 
recorded for one minute. A: control, Po=36.6%; B: 0.5 µM K201, Po=12.4%; C: 1 µM 
K201, Po=10.0%; D: 10 µM K201, Po=0.5%. (C- close state; O1- open state for the first 
channel; O2 – open state for the second channel.) 
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Fig 3.2 Concentration dependent inhibition of RyR2 by K201 
This graph was generated from data such as that presented in Fig 3.1. Open probability 
normalized to 1.0 for control is plotted vs. [K201] (●). Plots are representative of 6 
independent experiments. Error bars shown are the SE. 
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3.2 THE DIOXOLE DERIVATIVE OF K201 IS A MORE POTENT INHIBITOR 
OF RYR2 THAN K201 
In a previous study, we showed that the dioxole derivative of K201 is a stronger electron 
donor than is K201[39]. In this section, the inhibitory effect of the dioxole derivative of 
K201 was tested on the calcium release channel (RyR2) isolated from sheep heart 
sarcoplasmic reticulum. It is shown to inhibit single channel activity at lower 
concentrations than K201, and it shows a similar concentration dependent inhibition of 
RyR2 as was observed on RyR1 (Fig3.8). 
The same experimental conditions were used as in testing K201. Concentrations of the 
dioxole derivative ranging from 0~10 µM were added to the cis chamber of RyR2 
channels incorporated into an artificial at concentrations of 0, 0.05, 1 and 5 µM (fig 3.3). 
Fig 3.3 shows representative traces of 5 independent experiments carried out under the 
same condition. An inhibition of the single channel activity was frequently observed 
following an addition of the K201 derivative at concentrations as low as 50 nM. Addition 
of 0.5 µM of the dioxole derivative of K201 suppressed channel activity by 
approximately 50% (Open probability was decreased from 9.9% to 4.8%). The open 
probability decreased to ~ 5% of control as drug concentration increased up to 5 µM. No 
further inhibition was observed at higher drug concentrations. 
In figure 3.4, the normalized average open probabilities were plotted versus drug 
concentration and fitted to a four parameter logistic curve in Sigma Plot 10.0. The IC50, 
the drug concentration that half maximally inhibited release channel activity, was 
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0.4±0.18 µM. Compared with the IC50 for K201, the dioxole derivative was 2.5 times 
more potent in inhibiting the cardiac CRC than was K201. 
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Fig 3.3 RyR2 is inhibited by the 1,3 dioxole derivative of K201 
Representative traces of RyR2 channel activity at 0.1 µM free [Ca
2+
], 1 mM ATP on cis 
side: 400 mM CsMeSO4 on both sides of bilayes and -36 mV holding potential. 2s 
representative trace excerpts are shown. Open probabilities were obtained from traces 
recorded for one minute. A: control, Po=9.9%; B: 50 nM of the dioxole derivative of 
K201, Po=8.2%; C: 1 µM of the dioxole derivative of K201, Po=2.0%; D: 5 µM the 
dioxole derivative of K201, Po=0.04%. (C- close state; O1- open state for the first 
channel.) 
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Fig 3.4 Concentration dependent inhibition of RyR2 by the 1,3 dioxole derivative of 
K201  
This graph was generated from traces similar to Fig 3.3. Open probability normalized to 
1.0 for traces is plotted vs. [1,3 dioxole derivative of K201] (●). Plots are representative 
of at 5 independent experiments. Data shown is the mean ± SE. 
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3.3 4-METHOXY-3-METHYL- PHENOL INHIBITS RYR2 AT LOWER SALT 
CONCENTRATIONS 
We have previously shown that 4-Methoxy-3-Methyl phenol (4-MmC) inhibits the RyR1 
at low sub-micromolar concentration in a high salt environment [39]. In this section, the 
inhibitory effect of the 4-MmC was tested on the cardiac calcium release channel under 
two different conditions at a relatively low salt concentration and at a high salt 
concentration. Fig 3.8 shows 4-MmC is a more potent inhibitor of RyR2 than is K201 or 
its dioxole derivative when bilayer experiments with 4-MmC are carried at low salt 
concentrations. However, activation of the calcium release was observed at high salt 
concentration with additions of 4-MmC. 
The effect of 4-MmC on single channel activity was tested using the protocol described 
in section 2.2 except that the cesium methanesulfonate concentration was reduced to 250 
mM instead of 400 mM. Additions of 0.1 µM Ca
2+
 and 1mM ATP were added to the cis 
chamber of the bilayer setup to mimic the physiological environment in the cell. Different 
doses of 4-MmC ranging from 50 nM~10 µM, were added to the cis chamber. Four 
representative traces at 4-MmC concentrations of 0, 0.05, 1 and 10 µM were presented in 
fig 3.5. An inhibition of single channel activity was observed following an addition of 4-
MmC at concentrations as low as 50 nM. The addition of 0.1 µM 4-MmC suppressed 
channel activity by around 40% (Open probability decreased from 50.0% to 30.0%). The 
open probability was decreased even more as the drug concentration increases up to 1 
µM. No further inhibition was observed at higher drug concentrations. 
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In figure 3.6, the normalized average open probabilities were plotted versus drug 
concentration and fit to a four parameter logistic curve in Sigma Plot 10.0. The IC50, the 
drug concentration that half maximally inhibits release channel activity, is 0.14±0.04 µM. 
Compared with the IC50 for K201 and 1,3 dioxole derivative of K201, the 4-MmC is a 
more potent inhibitor of RyR2. 
In contrast, fig 3.7 shows that the 4-MmC activates the calcium release channel at high 
salt concentration (400 mM). The normalized average open probabilities were plotted 
versus drug concentrations. Each data point is representative of at least 5 experiments. 
With the addition of 50nM 4-MmC, the channel open probability was increased by more 
than a factor of two. Further activation was observed at higher drug concentration. 
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Fig 3.5 RyR2 inhibited by the 4-methoxy-3-methyl-phenol at relatively low salt 
concentration 
Representative traces of RyR2 channel activity at 0.1 µM free [Ca
2+
], 1 mM ATP added 
to cis side: 250 mM CsMeSO4 on both sides of the lipid bilayer and -36 mV holding 
potential. 2 s representative trace excerpts are shown. Open probabilities were obtained 
from traces recorded for one minute. A: control, Po=50.0%; B: 50 nM 4-MmC, Po=35.9%; 
C: 1 µM 4-MmC, Po=1.9%; D: 10 µM 4-MmC, Po=0.4%. (C- close state; O - open state.) 
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Fig 3.6 4-methoxy-3-Methyl-phenol is a potent inhibitor of the RyR2 at low salt 
concentrations 
This graph was generated from the data similar to that shown in Fig 3.5. Open probability 
normalized to 1.0 for control, traces is plotted vs. [4-methoxy-3-Methyl-phenol] (●). 
Plots are derived from the average +/- SE from 5 independent experiments. 
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Fig 3.7 4-methoxy-3-methyl-phenol activates the cardiac CRC at high salt concentrations 
Open probability normalized to 1 is plotted vs. [4-methoxy-3-Methyl-phenol]. Data 
shown is the average normalized Po ± SE (n=5). 
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Fig 3.8 Comparison of inhibitory potency of three drugs on RyR2  
This graph was generated from the data shown in Fig 3.2, 3.4 and 3.6. Open probability 
normalized to 1.0 for control, traces are plotted vs. K201(), 1,3 dioxole derivative of 
K201 (●) and 4-MmC(▼) concentrations. Plots are derived from the average +/- SE from 
5 independent experiments. 
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3.4 THREE DRUGS DECREASE THE CHANNEL OPEN PROBABILITIES AND 
OPEN TIMES BUT DON’T AFFECT THE CHANNEL CLOSE DURATION 
It has recently been shown that the beneficial actions of drugs as RyR2 inhibitors stem 
from their ability to block RyR2 channels only in the open state.[42] For the three drugs 
that we studied in this project, they all showed decreases in open probability and open 
time without significantly increasing the channel closed time at concentration less than 
the IC50. Average closed times for channels were calculated using the method described 
in section 2.2.3.  
Fig 3.9 and 3.10 shows the closed and open time for K201 at concentrations less than 
their Ki (less than or approximately equal to their IC50). The addition of 1µM K201 
reduced the channel open probability by more than half and open time by 50% (p=0.08), 
but doesn’t significant change the closed duration (p=0.97). At higher drug 
concentrations, channel average close state duration increased by a factor of more than 
100 compared to control (not shown). The absolute value of average closed time and 
open time for controls are equal to 4.8±2.4 ms and 2.1±0.6 ms, respectively. 
Similar results were obtained with the dioxole derivative of K201 and 4-MmC. In fig 
3.11 and 3.12, we show that the dioxole derivative of K201, in a manner similar to K201, 
shows no signifivant effect on the closed time (p=0.45) of RyR2 at concentration as high 
as 0.5 µM (where Po has decreased to ~50%), while open time decreased by around 40% 
(p=0.049) The absolute values of the average closed time and open time for controls are 
12.3±3.9 ms and 1.6±0.6 ms, respectively. Fig 3.13 and 3.14 show the open time and 
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close time change with the addition of 4-MmC. The same trend was observed as K201 
and the dioxole derivative of K201 (p=0.42 for the close time and p =0.034 for the open 
time at 1 µM K201). The absolute value of average closed time and open time for 
controls are 1.5±0.4 ms and 2.1±0.8 ms, respectively. 
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Fig 3.9 K201 has no significant effect on channel closed time (τc). 
Normalized average closed time vs. concentration of the dioxole derivative of K201.  
Absolute value of average closed time for control is 4.8±2.4ms. Each points represents 
the average of at least four measurements ± standard error.  
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Fig 3.10  K201 decreases channel open times (τo). 
Normalized average open time vs. concentration of K201.  Absolute value for average 
open time for control is 2.5±0.6 ms. Each points represents the average of at least four 
measurements ± standard error.  
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Fig 3.11 1,3 dioxole derivative of K201 has no significant effect on channel closed time 
(τc). 
Normalized average closed time vs. concentration of the dioxole derivative of K201.  
Absolute value for average closed time for control is 12.3±3.9 ms. Each points represents 
the average of at least four measurements ± standard error.  
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Fig 3.12 1,3 dioxole derivative of K201 decreases channel open times (τo). 
Normalized average open time vs. concentration of the dioxole derivative of K201.  
Absolute value for average open time for control is 2.5±0.8 ms. Each points represents 
the average of at least four measurements ± standard error. 
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Fig 3.13 4-Methoxy-3-Methyl-phenol has no significant effect on channel closed time 
(τc). 
Normalized average closed time vs. concentration of 4-MmC.  Absolute value for 
average closed time for control is 1.5±0.4 ms. Each points represents the average of at 
least four measurements ± standard error.  
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Fig 3.14 4-Methoxy-3-Methyl phenol decreases channel open times (τo). 
Normalized average closed time vs. concentration of 4-MmC.  Absolute value for 
average open time for control is 2.1±0.8 ms. Each points represents the average of at least 
four measurements ± standard error.  
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CHAPTER IV 
DISCUSSION 
In this study, two new potent RyR inhibitors were synthesized which are derivatives of 
known RyR modulators, 4-chloro-3-methyl phenol (4-CmC) and K201. 4-CmC is a 
effective activator of both  RyR1 and RyR2 at sub millimolar concentration [43] . By 
replacing the chloro in the 4 position with a methoxy group, we have converted an 
electron acceptor into an electron donor and converted a channel activator into a potent 
channel inhibitor (Section2.4.2). In a similar manner, synthesizing the dioxole derivative 
of K201 converts a RyR inhibitor into a more potent electron donor and significantly 
increases its effectiveness as a channel inhibitor. This nontraditional approach toward 
drug design was motivated by our earlier observations that all RyR activators tested were 
electron acceptors, while channel inhibitors were electron donors. Moreover, there is a 
correlation between the effectiveness of these drugs and their potency as either electron 
donors (inhibitors) or acceptors (activators) [12]. 
K201 is a strong electron donor which inhibits both the skeletal [44] and cardiac muscle 
RyR [45, 46]. It has been shown to have both antiarrhythmic and cardioprotective 
properties. These beneficial effects on the heart appear to be caused by its ability to 
decrease the diastolic calcium leak mediated by the cardiac ryanodine receptor. Much 
effort has been directed toward understanding how K201 functionally modifies RyR2, but 
the basic mechanism of its action still remains unclear.  
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Some research groups propose that K201 stabilizes the RyR by causing the reassociation 
of the FKBP12/RyR1 complex in skeletal muscle and the FKBP12.6/RyR2 complex in 
cardiac muscle [47]. This interpretation has been challenged by the observation that K201 
almost completely inhibits the Ca
2+
 leak from normal dog heart SR under conditions in 
which the FKBP12.6 has completely dissociated from RyR2 [48]. Our previous 
observation has also shown that K201 suppressed the channel activity from normal and 
FKBP12 depleted RyR1 with similar potency. Moreover, RyR1 does not reassociate with 
FKBP12 in the presence of 20 µM K201- a concentration that significantly inhibits single 
channel activity [39].  
Our single channel experiments have shown that the inhibitory effect of K201 is four 
times more potent in suppressing the cardiac calcium release channel activity than 
skeletal muscle channel activity. The IC50 for inhibiting the RyR2 is 1.13 µM ± 0.68 µM 
compared with 3.98 µM ± 0.79 µM for RyR1. The difference in inhibitory potency might 
be caused by structural differences between RyR1 and RyR2, which leads to a different 
number of available drug binding sites. Alternatively, it is also possible that the binding 
affinity of K201 to RyR2 is larger than the binding affinity to RyR1or that RyR2 accepts 
electrons from K201 more readily than RyR1 does. 
Previous publications have shown that K201 is not specific for the SR Ca
2+
 release 
channel. It has been reported that K201 nonspecifically inhibited transmembrane Na
+
, 
Ca
2+
 , and K
+
 currents [49] and that the cardioprotective effects of the drug were 
abolished when hearts were pretreated with inhibitors of protein kinase C [50]. K201 can 
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also alter the gating of the dihydropyridine receptor [45] and has a natriuretic effect on 
the glomerular filtration rate [51]. Due to these multiple side effects, it is unlikely to be 
developed as a pharmaceutical product.   
The 1,3 dioxole derivative of K201 is obtained by selective modification of  K201 [46], 
resulted in a compound with enhanced electron donor properties. As expected, the 
dioxole derivative is a more potent electron donor, as well as a stronger channel inhibitor 
than K201. It suppresses both RyR1 and RyR2 activity at sub micromolar concentrations.  
We also have observed that the inhibitory effect of the dioxole derivative of K201 at the 
single channel level is reversible. Changing solutions following addition of the dioxole 
derivative restores the channel activity. This observation can be explained by the 
hypothesis in our previous publication that non thiol electron acceptors or donors interact 
with the ryanodine receptor by forming a reversible charge transfer complex.  
A similar approach was used to develop a new drug targeting the RyR with enhanced 
electron donor properties by modifying the channel activator 4-CmC. 4-MmC is the most 
effective inhibitor among the three drugs examined in this study. The IC50 for 4-MmC in 
inhibiting RyR2 activity is 0.14 µM ± 0.04 µM. Unlike K201 and the dioxole derivative 
of K201, the inhibition effect of 4-MmC on RyR2 were only observed at lower salt 
concentration than has previous been examined (250 mM CsMeSO3), while channels 
were activated at higher salt concentration (400 mM CsMeSO3).  It appears that 4-
MmC’s ability to inhibit RyR2 involves an electrostatic interaction. We are not certain 
why 4-MmC activates RyR2 at high salt concentrations but inhibits channel activity at 
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lower salt concentration. The salt concentration inside of most cells is around 160 mM. 
At this low salt concentration, SR vesicles do not fuse to the artificial bilayers. As a 
compromise between reproducing physiological conditions and the necessity of the SR to 
fuse to the bilayer (high salt conditions), we examined channel activity at a salt 
concentration of 250 mM. Under these conditions, 4-MmC inhibits RyR2.  
It has recently been shown that the two RyR2 inhibitors, tetracaine and flecainide differ 
in their mode of action. While tetracaine inhibits channel activity by increasing channel 
closed time, flecainide decreases channel open time, but has little or no effect on the 
average closed time of RyR2 [42, 52]. Authors of these studies postulate that the 
beneficial action of flecainide stem from its peculiar ability to block RyR2 channels only 
when the channel is in the open state [42]. In section 3.4, we show that the three drugs 
tested in this study, in a manner similar to flecainide, show no significant effect on the 
closed time of RyR2 at concentrations at or less than their IC50. The drugs we have tested 
appear to inhibit open RyR2 channels by reducing the RyR2 open channel mean burst 
duration.  
Moreover, consistent with our results at the single channel level, three drugs showed 
significant anti-arrythmogenic effect when they were tested at the whole heart level and 
the whole animal level. Addition of 1.0 µM of the dioxole derivative of K201 suppressed 
EADs and restored the normal AP profile in an adult female rabbit heart. 4-MmC and 
K201 were tested on FKBP12.6+/- mice for ventricular tachycardia. The data revealed 
ventricular arrhythmias in 60% of the FKBP12.6+/- mice. However, treatment with 4-
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MmC (a significantly more potent anti-arrhythmic compound) completely eliminated 
ventricular tachycardia. These studies were done by our collaborators Dr. G. Salama at 
the University of Pittsburgh and Dr Xander Wehrens at Baylor College of Medicine. 
Although these drugs inhibit single channel activity and the Ca
2+
 leak associated with HF 
and ventricular arrhythmias, they don’t affect the normal action potential, nor do they 
inhibit normal excitation contraction coupling. It is still unclear why these drugs only 
affect defective channels. It is possible most of the binding sites for these drugs are in the 
mouth of RyR, which is accessible when the channel opens. A leaky channel opens for a 
longer period of time while the normal channel opens and closes relatively quickly. When 
the channel opens for a longer period of time, the drug has enough time to bind and 
inhibit channel activity by decreasing the open time of the channel. Normal channels, 
presumably don’t open for a long enough period of time for drug binding to the 
corresponding sites. Alternatively, during normal EC coupling there may be steric 
considerations that hinder the binding of these drugs. 
Although the drugs described in this study show beneficial effects in stabilizing the 
calcium release channel of both skeletal and cardiac muscle SR at the single channel level, 
they exhibited no effect on measurements of high affinity ryanodine binding. Unlike most 
channel inhibitors, we have demonstrated that these drugs close down both RyR1 and 
RyR2, yet they don’t inhibit high affinity ryanodine binding. It appears as if these are two 
conformationally closed states of the RyR, one which results in inhibition of ryanodine 
binding and one which has no effect on ryanodine binding.  
66 
 
We have previously observed a good correlation between a drug’s ability to act as an 
electron donor, and its ability to close down channel activity [12]. These new drugs that 
we have developed inhibit channel activity at submicromolar concentrations. At these 
low concentrations, our assay for measuring electron donor properties loses its sensitivity. 
This assay has to be improved in order to effectively compare electron donor properties 
of new more potent drugs.  
Future work related to this project should be focused on two directions. In this study, the 
inhibitory potency of K201, the dioxole of K201 and 4-MmC were compared. 4-MmC 
inhibited RyR2 channel activity at lower salt concentration (250 mM CsMeSO4), while 
the other two drugs inhibited channel activity at high salt concentrations (400mM 
CsMeSO4). It would be more persuasive if we could compare the inhibitory effects of 
these three drugs under the same experimental conditions. More single channel 
experiments should be done to test the K201 and its dioxole derivative at low salt 
concentrations. In order to further test our hypothesis that it’s potency as an RyR 
inhibitor, and to determine if more potent electron donors are more effective inhibitors of 
arrhythmogenic activity, more new drugs need to be synthesized and tested at the single 
channel level, at the whole heart level and at the whole animal level. Furthermore, if 
these new drugs inhibit channel activity by deceasing the channel open time, and they 
seem to single out “leaky Ca2+ channels” it would be interesting to see if these drugs fail 
to inhibit channel activity if the Mg
2+
 concentration is increased to approximately 1 mM 
concentration. Increasing the Mg
2+
 concentration to a more physiological range is known 
to decrease the channel open time and result in more rapid flickering of the channel. If 
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under these conditions these drugs fail to inhibit single channel activity, this offers an 
explanation of why these drugs do not alter normal E-C coupling in normal cardiac 
preparations.  
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